Technical Analysis for AGE - AgeX Therapeutics, Inc.
ADX | Long-Term | Intermediate-Term | Short-Term |
---|---|---|---|
Weak or Absent | N/A | Up | Up |
See historical AGE trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Feb 20 | Inside Day | Range Contraction | 0.00% |
Feb 20 | Upper Bollinger Band Touch | Strength | 0.00% |
Feb 19 | 180 Bullish Setup | Bullish Swing Setup | -5.63% |
Feb 19 | Pocket Pivot | Bullish Swing Setup | -5.63% |
Feb 19 | Above Upper BB | Strength | -5.63% |
Feb 19 | Upper Bollinger Band Touch | Strength | -5.63% |
Feb 15 | Inside Day | Range Contraction | 8.11% |
Feb 14 | 20 DMA Support | Bullish | 4.86% |
Feb 14 | MACD Bullish Signal Line Cross | Bullish | 4.86% |
Feb 13 | Crossed Above 20 DMA | Bullish | 10.49% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which AgeX plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, AgeX, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. AgeX also markets Cytiva® comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.
Biotechnology Life Sciences Biology Diseases Stem Cells Cell Biology Tissue Engineering Degenerative Disease Cloning Stem Cell Telomerase
Biotechnology Life Sciences Biology Diseases Stem Cells Cell Biology Tissue Engineering Degenerative Disease Cloning Stem Cell Telomerase
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength | |||
Summary: | Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. |
See more AGE news...
Indicators
Indicator | Value |
---|---|
52 Week High | 5.95 |
52 Week Low | 1.13 |
Average Volume | 111,392 |
200-Day Moving Average | 0.0 |
50-Day Moving Average | 3.8062 |
20-Day Moving Average | 4.1425 |
10-Day Moving Average | 4.276 |
Average True Range | 0.4319 |
ADX | 21.58 |
+DI | 25.4812 |
-DI | 12.0924 |
Chandelier Exit (Long, 3 ATRs ) | 3.5443 |
Chandelier Exit (Short, 3 ATRs ) | 4.9957 |
Upper Bollinger Band | 4.7111 |
Lower Bollinger Band | 3.5739 |
Percent B (%b) | 0.84 |
BandWidth | 27.452022 |
MACD Line | 0.1341 |
MACD Signal Line | 0.0924 |
MACD Histogram | 0.0417 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.00 | ||||
Resistance 3 (R3) | 5.05 | 4.94 | 4.92 | ||
Resistance 2 (R2) | 4.94 | 4.82 | 4.92 | 4.90 | |
Resistance 1 (R1) | 4.74 | 4.75 | 4.68 | 4.69 | 4.87 |
Pivot Point | 4.63 | 4.63 | 4.60 | 4.60 | 4.63 |
Support 1 (S1) | 4.42 | 4.50 | 4.37 | 4.37 | 4.19 |
Support 2 (S2) | 4.31 | 4.43 | 4.29 | 4.16 | |
Support 3 (S3) | 4.11 | 4.31 | 4.14 | ||
Support 4 (S4) | 4.06 |